ࡱ> 1305%` 0bjbj N̟̟3".G 4 x&x&x&h&4'< SA\'('p'''72>u22 @@@@@@@$BhgE@ W41@72W4W4@'' A666W4^Z' '@6W4@66V"?@ ?'P' w~x&4^b? V@|#A0SAn?xE5E?E ?p2Z2@6/34c3222@@+6^222SAW4W4W4W4   d         Form 2.0 SupplementEvaluation Proposal Guidelines 1. Product & supplier details It is important to state both the type or generic name for the product as well as the brand name. This will ensure the product is easily identifiable by all committee members regarding the product and its intended use. For example: Comfeel is a brand of hydrocolloid dressing. This also eliminates the bias towards a particular product that is commonly identified by a brand name. For example: jelco is a term commonly used by hospital personnel when describing all types of IV cannula even though this is a brand specific to a particular company. Probity Ensure all members of the evaluation panel are aware of their responsibilities in regards to probity. 2. Compliance Medical devices sold in Australia are required to be listed on the Australian Register of Therapeutic goods. The federal body responsible for the assessment and monitoring of products placed on this register is the Therapeutic Goods Administration (TGA). When products or devices are listed, registered or included on the TGA register an ARTG number is allocated to that particular product or, in some circumstances, group of products. The supplier will be able to provide this information along with all compliance certification for their products. Australian standards or Australia/New Zealand standards may also apply to the product. These standards include either mandatory or desirable criteria relating to the function, materials and testing methods for a product. A copy of the Australian and Australian /New Zealand standards are available from the RCH library. 3. Financial assessment The usage figures and comparative costings can be obtained from Material resources. Consideration of the following also needs to be taken into account when providing a financial assessment as organisational costs may not be accurately displayed via a simple cost comparison: 3.1 Value of risk reduction vs. increased cost For some products, it is not feasible to simply address the unit cost comparisons when performing a financial assessment. An increase in the product cost may outweigh the potential risk to the organisation. This may include, for example, the financial support of a staff member returning a positive result from a needle stick injury or a patient permanently debilitated from a clinical incident. 3.2 Dependence on other equipment or products Ask whether this particular product is reliant on the purchase of other items to be clinically effective in its use. For example: A temperature probe that is cheaper than the current one being used but requires numerous adapter cables in order to be used with the hospitals monitoring equipment or new stockings that are of clinical benefit are reliant on the use of applicators at a significant cost. 3.3 Change in labour time to perform a function or task The cost advantage of some products lies within the time it takes to perform a task. It is difficult to quantify because the cost benefits are shown in man hours. When discussing the labour time that would be reduced, be careful to outline what specific increased productivity will be gained and how it will be shown. Realistically, labour hours or EFT will not be cut in response to the introduction of a product. 3.4 Change from reusable to single use items The decisions to change from reusable to single use items will arise for various reasons. It can be in response to DHS directives, clinical incidents involving safety, the inappropriate reusing of an item or deletion of a product by a supplier. 3.5 Life cycle costing (Only to be used for capital equipment purchases) The principles of life cycle costing address the cost of ownership of an item (generally an equipment item) incurred throughout its whole life not just at the time of acquisition. What may be the cheapest upfront may not be the most appropriate when ongoing operational costs, maintenance and disposal costs are considered. Below is a Life Cycle Costing model to assist when determining accurate total cost of a device. Assistance can be obtained from the biomedical engineering department regarding equipment life, operating costs and disposal value.  Reference Health Purchasing Victoria Guidelines for Product Management Draft Document 2006 4. Practice assessment Document if and how practices are required to be changed to ensure the relevant departments (e.g. Clinical quality & safety) are involved and have an opportunity to discuss education and scheduling requirements. 5. Risk assessment The risk assessment of any device is to determine its safety by identifying hazards and estimating the risks associated with the use of the device. When performing a risk assessment, some hazards to consider: Energy - electricity, heat, magnetic field, pressure, mechanical force, ionising radiation Biological cross infection, contamination, carcinogenicity, allerginicity, toxicity Environmental Electromagnetic interference, incompatibility with other devices, likelihood of being used outside prescribed environmental conditions, inadequate power supply to support device, incompatibility with other devices User interaction inadequate labelling, potential use by unskilled/untrained personnel, inadequate operating instructions, insufficient warning of side effects, potential misuse by staff Functionality loss of mechanical integrity, indeterminate end of life date, improper re-use, inadequate maintenance Refer to the risk assessment tool to document possible hazards and risk analysis.  SHAPE \* MERGEFORMAT  6. Trial Process The most important part of the trial process is to identify the key stakeholders and engage them in the evaluation process. The predominant users of a product type can be identified from usage reports obtained from Material resources or by communicating with various departments that would potentially use that type of product. Alternatively, a broadcast e-mail or memo about the proposed evaluation will allow staff and departments to volunteer to participate in the evaluation. Ensure the format of the trial is suitable for adequate evaluation of the product/s. Determine how often a product will need to be used by a clinician to assess its suitability and comment on its performance. At times, it may be necessary to extend trial periods if clinicians have not had adequate opportunity for evaluation for any number of reasons. This may need to be assessed at the end of the initial trial period. Be mindful, that all suppliers are to be given equal opportunity for evaluation and trial periods may need to be extended for all parties. Alternatively, ensure set trial criteria are in place and all suppliers are aware of how these situations will be managed. Identify the scope of the trial including how many suppliers & brands will be trialled. Make sure the market has been investigated and all suppliers given the opportunity to respond to the proposed trial of the product. If more than one brand (supplier) is being evaluated, identify how each supplier/brand will be ensured the same level of attention. Ensure all participants are aware of their responsibilities in regard to probity. 7. Trial feedback The generic RCH trial form is to be used for all product trials. If this form is not appropriate, comment on its limitation and issues for your product trial and include a revised version for approval by the evaluation committee. Develop the key criteria for the evaluation of the product. This ensures key features unique to this product type are critiqued and the fundamentals of its performance can be assessed. Specify who will be responsible for distributing and collecting trial evaluations. Preferably this should be a hospital staff member. 8. Communication strategy Document how the key stakeholders will be informed of the trial and how they will be kept up to date during the trial period. This will depend on the product being trialled but may extend to broadcast e-mails, evaluation group meetings, and general bulletins or personalised correspondence, e.g. Letters to sessional medical staff. 9. Evaluation tool It is sufficient to state that the standard RCH product evaluation tool is to be used for this trial. More specific information will be required if the evaluation tool deviates from the standard. In this situation, a detailed description about the revised tool will need to be provided as well as documentation supporting the need for its use. For further information please refer to  HYPERLINK "http://www.rch.org.au/cpa/products.cfm?doc_id=11307" Clinical Products Advisory : Selecting Products     Clinical Products Evaluation Committee  EMBED PBrush  Clinical Products Evaluation Committee V1.1 Page  PAGE 2 of  NUMPAGES 4 Clinical Products Evaluation Committee  EMBED PBrush  Clinical Products Evaluation Committee V1.1 Page  PAGE 1 of  NUMPAGES 4 Life cycle cost = Capital cost + (estimated Equipment Life x Annual operating costs) disposal value Identify the interaction the device will have with: Patients Clinicians Hospital personnel General public Identify any possible hazards with the product Identify key personnel to be consulted for identification of hazards and subsequent risk: Infection Control OH&S Biomedical engineering CSSD Engineering services Material resources Nursing Education Clinical Nurse Consultants Clarify intended use of the product within the hospital Identify the key areas where the product will be used Estimate the risk associated with each hazard Low Acceptable risk, risk identification and awareness is all that is required for risk analysis Medium Moderate risk; aim to reduce risk and implement management strategy prior to the use of product including during trial High Significant risk to patient and/or staff will need to be eliminated before product used in hospital, consider risk too high for possible trial & implementation. Document any identified hazards, estimation of associated level of risk and proposed management during trial and possible use within the hospital. The overall risk rating for the product is the highest level of risk of all the assessed hazards Risk Assessment Tool Risk assessment tool 3456U l\]_ !#[/0()+tø|jhQ<h%OJQJUh%OJQJh{QRh%5OJQJhQ<h%OJQJhQ<h%5OJQJ\h%5OJQJ\h+h%CJ^JaJ h%56CJOJQJ^JaJ&h+h%56CJOJQJ^JaJhDh%CJaJ0450kd$$Ifl0 $  t&&0$644 l` &ap&&yt~$$Ifa$gd~l $Ifgd~lgd%3*a+056U ( kl]^!"[0)*tgd%3o+( "'${$|$$gd%(|$$&&#(6()))))))ʽʦʽۊ|n|n\n#jhGnhGn6OJQJU\hGnhGn6OJQJ\hGnh%6OJQJ\h%5OJQJ\!jhch%OJQJU^J,jhch%OJQJU^JmHnHuhch%OJQJ^J!jhch%OJQJU^Jh%hQ<h%5OJQJ\h%OJQJhQ<h%OJQJ$v%1&&&&"(#(6())))1*2*3*5*6*8*9*;*<*>*?*z*{*|*  r D%gd%Bgd%gd%gd%))*/*0*1*2*3*4*6*7*9*:*<*=*?*e*f*g*v*w*x*y*z*{*|*~****غtlh`XMhGnhGnCJaJhGnCJaJh ZCJaJh~jh%BU%j)J h%BOJQJUVnH tH jh%BUh%Bhg@h%BCJOJQJaJhHUjhHUUh%CJaJh%hGnh%6OJQJ\hGnhGn0J6OJQJ\#jhGnhGn6OJQJU\)jAhGnhxG6OJQJU\|*}*~**** + + +++_+`+a+b+c+d+e+f+g+h+i+j+k+l++$a$gd%  r D%gdCgd Zgd%******************++ + + + + ++5+;+@+qcR hGnhGnCJOJQJ^JaJhGnCJOJQJ^JaJ h=h ZCJOJQJ^JaJh%CJaJj hCU%j)J hCOJQJUVnH tH jhCUhChg@hCCJOJQJaJh~h%h Zhf?CJaJmHnHujhGnCJUaJhGnhGnCJaJjhGnhGnCJUaJ@+A+G+H+I+J+N+O+Y+Z+[+\+]+^+_+`+a+l+++++F,G,v,w,,,Y-Z-------ǴǴ꧚wsfsfsfwfsf_sfsf h'*h%hoh%OJQJ^Jh%h%OJQJ^JhM"h%OJQJ^JhhHUh~h=h ZOJQJ^Jh=h%OJQJ^J%hf?CJOJQJ^JaJmHnHu#jhGnCJOJQJU^JaJ hGnhGnCJOJQJ^JaJ)jhGnhGnCJOJQJU^JaJ#+++,,$,7,F,G,v,w,,,,,--,->-Y-Z----- $h^ha$gd% $ & Fa$gd% $ & Fa$gd%gd%$a$gd%---\..//00z0{0000000gd%gd%gd% $ & Fa$gd%gd%--\.b...//00z0{0000000h%CJaJh\! hVh% h h%hrh%OJQJ^Jh%hoh%OJQJ^Jhoh%5OJQJ^J= 0&P 1h/R :p~. A!"Q#n$% = 0&P 1h/R :p~. A!n"#p$% 21h:p%. A!"#$% $$If!vh5a 5#va #v:Vl  t&&$6,55` &p&&yt~Dd o D  3 @@"?DyK yK hhttp://www.rch.org.au/cpa/products.cfm?doc_id=11307Dd r030  # AbF\T=&io"^ n\T=&ioPNG  IHDRnJ}sRGB pHYs.>IDATx^ێ6 D3~aKdUeLR, W+>… <߿MU~yZS(y(Bޞ)#;6`n=Y-YDHeʑ[.׀"X!4"YzaHPFVL!1WYZzi<[EPXEqSrJqqia;{7fC;A:={3 +|jOzl"[\t6=jBvr|!jRKCۃ"Q̷LMx% N6k HV("0\xڼRAj,SŞ)DhdfAԨNqutyʹ٢B fƺߎP;\\5~fb٧0Iی>׳P;A.:ҳ󁟵R>`ٺ^߂(F۴ܤº55峧?u䙣<&E{2<+!{|<f/Gh DF(]VjwRʹUQKB RgPՄNW' ?I_++JB_0!ڤ""ֹOooETGZ0e+!\-K"w)ЎgQ8?ޭ[]!~]Gr)*G̬9[Q .*a/@ZaSd! AOJ" ~8FUDn/Ai{ flL;Xnb/ l#d1_*Br LE=XQ>Š(e7G^3f\P]ۙ[XRCU>Ӗ̈́vK6&I$>/N,lUFƟwQқ- g["6+pJϔ)Aߵܝs} l.rxƠDq$v7>AY#DzgacOʬVlg d(b:+E,O^F>\Ep#+,tLҋRjPKpB,ä V);B8L@ a.ä V);B8L@ a.ä V);B8L@ a.ä V);yiFʡIENDB`Dd r030  # AbF\T=&io"( n\T=&ioPNG  IHDRnJ}sRGB pHYs.>IDATx^ێ6 D3~aKdUeLR, W+>… <߿MU~yZS(y(Bޞ)#;6`n=Y-YDHeʑ[.׀"X!4"YzaHPFVL!1WYZzi<[EPXEqSrJqqia;{7fC;A:={3 +|jOzl"[\t6=jBvr|!jRKCۃ"Q̷LMx% N6k HV("0\xڼRAj,SŞ)DhdfAԨNqutyʹ٢B fƺߎP;\\5~fb٧0Iی>׳P;A.:ҳ󁟵R>`ٺ^߂(F۴ܤº55峧?u䙣<&E{2<+!{|<f/Gh DF(]VjwRʹUQKB RgPՄNW' ?I_++JB_0!ڤ""ֹOooETGZ0e+!\-K"w)ЎgQ8?ޭ[]!~]Gr)*G̬9[Q .*a/@ZaSd! AOJ" ~8FUDn  !"#$%&')*+,-./2789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry  F4Data (WordDocument NObjectPool Kw_1251715369 Fw~w~Ole PRINT6CompObjM  FPBrushPBrushPBrush9qOh+'0 ( H T `lt| EVALUATION PROPOSAL GUIDELINES^  Wa=a  =aA n(n8ObjInfo Ole10Native1TableFSummaryInformation( BMn6(n8/Ai{ flL;Xnb/ l#d1_*Br LE=XQ>Š(e7G^3f\P]ۙ[XRCU>Ӗ̈́vK6&I$>/N,lUFƟwQқ- g["6+pJϔ)Aߵܝs} l.rxƠDq$v7>AY#DzgacOʬVlg d(b:+E,O^F>\Ep#+,tLҋRjPKpB,ä V);B8L@ a.ä V);B8L@ a.ä V);B8L@ a.ä V);yiFʡIENDB`RCH Normal.dotVanessa Cilia4Microsoft Office Word@^в@0Z@՜.+,D՜.+,h$ hp   Women's and Children's Health>""' EVALUATION PROPOSAL GUIDDocumentSummaryInformation8 PCompObjqELINES Title 8@ _PID_HLINKSA r4http://www.rch.org.au/cpa/products.cfm?doc_id=11307`  FMicrosoft Office Word Document MSWordDocWord.Document.89q      !"#J@J Normal$a$KHOJQJ_HmH sH tH R@R  Heading 1$@&a$5:@CJOJQJ\@\  Heading 2$<@& 56CJOJQJ\]^JaJDA@D Default Paragraph FontRi@R  Table Normal4 l4a (k(No List^O^ Heading 1 Char*5:@CJKHOJQJ_HmH sH tH hOh Heading 2 Char456CJKHOJQJ\]^J_HaJmH sH tH 4@4 &Header  9r 4 @"4 &Footer  9r ~@3 % Table Grid 1z:V0jj $a$6]6]6U@A6 Gn Hyperlink >*B*ph {3j$0F(  + !)  {3j$0FI    (N?N~N456U(kl] ^ ! " [  0 )*t3o+('{|v1" # 6 !!!!1"2"3"5"6"8"9";"<">"?"z"{"|"}"~"""" # # ###_#`#a#b#c#d#e#f#g#h#i#j#k#l####$$$$7$F$G$v$w$$$$$%%,%>%Y%Z%%%%%%%\&&''((z({((((((00 0 0 00000000000000000000000000000000000000000000000000000000000000000000000001"@0X00@0X00@0X00@0X00@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0X00000000000000000 0 0 0 00p000 0 0 0 0 0 0 0 00000000 0 0 0000000000000H45U(kl^ " [ *t3o+('{|v1" # 6 !!!!1"2"3"z"}"~""" # ###a##G$(000A0h 0B0e @0@0@0@0@0@0@0@00@0@0@0@0@0@0@:0@:0@:0@:0@:0@:0@:0@:0@%0@0@0@0@0@0@0@:0@ &0@ &0@ &0@ &0@ &0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@001\M@000000000lY0000840000 00-0000tz\M II-------------0)*@+-0 "#&5$|*+-0!$%0!!/"(_X3CE| &(0:!:!8+,@ +P(   | !<- 3  s"*?`  c $X99?| !<-h  3  "`7   h  3 "` l h  3 "`6C h  3 "`6 T  # 6 h  3 "`M% h  3 "`*y5- T   #   '!) h ! 3 !"`d "o H " # H # # H $ #  H %B # lCH &B # MH ' # %'H ( # )*h ) 3 )"` | H * # n n \ + 3  +1"`  B S  ? " # $ % & ' (*(+0z%Te"5t  _Toc152653503 _Toc156636922(2"2"( 4"  t"11(<<(B*urn:schemas-microsoft-com:office:smarttagscountry-region9*urn:schemas-microsoft-com:office:smarttagsState9*urn:schemas-microsoft-com:office:smarttagsplace 83"3"5"5"6"6"8"9";"<">"?"##(3"3"5"5"6"6"8"9";"<">"?"##(2"3"3"5"5"6"6"8"9";"<">"""""############################((3"3"5"5"6"6"8"9";"<">"?"`#a#(xBc x*i.WD0<6?j&h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHxBc ?j.WD                           %o' \!#=f? Z8L[RgGnRrwP~HUK5b&CxG=%B451"3"5"8";">"" #5#^#(@(P@UnknownGz Times New Roman5Symbol3& z Arial?& Arial Black9Garamond?5 z Courier New;Wingdings"1hD⹦dž>>!n4d""""2QHP ?2EVALUATION PROPOSAL GUIDELINESRCH Vanessa Cilia